We can now take advantage of rapid advances in healthcare science, new procedures and better use of data science and computing power. At the same time, healthy living and wellbeing are staying firmly in the spotlight. And of course, the 2020 pandemic changed the landscape of healthcare innovation forever.
Although traditionally seen as a source of relatively defensive growth, the rapid pace of change across the healthcare sector is opening up a new world of healthcare investment opportunities.
*Schroder International Selection Fund is referred to as Schroder ISF.
And why innovation is driving investment in the world’s health.
Global healthcare portfolio manager John Bowler weighs in
We’ve been managing healthcare portfolios since 200. Our team of 5 healthcare specialists have over 90 years of combined investment experience and look after US $10 bn of healthcare assets.
Benefit from diversification across five healthcare sub-sectors
1. Advanced therapies: gene therapy, precision medicines
2. Med tech: robotics, connected healthcare
3. Healthcare services: telehealth, healthcare management
4. Digital healthcare: biosensors and trackers, AI
5. Wellbeing: body and fitness, seeing and hearing
A focused, yet diverse portfolio for potential long-term returns
We look across the sector to construct a portfolio with 50 to 70 stocks that reflect our best ideas – and aim to deliver steady returns over the long-term.
Backed by insights from our dedicated data team
A team of 20+ data scientists, statisticians and mathematicians supplement traditional financial data with alternative data sets and techniques including artificial intelligence and machine learning to find companies that shape the future of healthcare.
In this webinar, John Bowler, fund manager of Schroder ISF Healthcare Innovation shares how he sees the crisis shaping the sector in the medium-term and the opportunities he sees.
You can find more information on the fund including literature and performance data on our fund centre.
Schroder ISF Healthcare Innovation
“The over 65s are the fastest-growing demographic group for the next 20 years. And government budgets are already under pressure – an immense driver of change, enabled by technology. Think gene therapy, immune therapy, smartphone GP appointments, AI diagnostics. Our unique team has the expertise and depth of experience to capture these opportunities.”
Fund Manager, Global Healthcare
This webpage does not constitute an offer to anyone, or a solicitation by anyone, to subscribe for shares of Schroder International Selection Fund (the “Company”). Nothing on this webpage should be construed as advice and is therefore not a recommendation to buy or sell shares. An investment in the Company entails risks, which are fully described in the prospectus.
Subscriptions for shares of the Company can only be made on the basis of its latest Key Investor Information Document and prospectus, together with the latest audited annual report (and subsequent unaudited semi-annual report, if published), copies of which can be obtained, free of charge, from Schroder Investment Management (Europe) S.A.
For Luxembourg, these documents may be obtained in English, free of charge, from the following link: www.eifs.lu/schroders.
For the UK, these documents may be obtained in English, free of charge, from the following link: www.eifs.lu/schroders.
The fund has the objective of sustainable investment within the meaning of Article 9 of Regulation (EU) 2019/2088 on Sustainability-related Disclosures in the Financial Services Sector (the “SFDR”). For information on sustainability-related aspects of this fund please go to www.schroders.com
Any reference to sectors/countries/stocks/securities are for illustrative purposes only and not a recommendation to buy or sell any financial instrument/securities or adopt any investment strategy.
Past Performance is not a guide to future performance and may not be repeated.
The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of investments to fall as well as rise.
Schroders has expressed its own views and opinions on this webpage and these may change. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy.
A summary of investor rights may be obtained from https://www.schroders.com/en/lu/private-investor/footer/complaints-handling/. For your security, communications may be recorded or monitored.
Issued by Schroder Investment Management (Europe) S.A., 5, rue Höhenhof, L-1736 Senningerberg, Luxembourg. Registration No B 37.799.
Distributed in the UK by Schroder Investment Management Ltd, 1 London Wall Place, London EC2Y 5AU. Registration No 1893220 England. Authorised and regulated by the Financial Conduct Authority.